Procedure for assessing the acceptability, in principle, of vaccines ...

Acknowledgments
Acknowledgements are due to the following experts and organizations for their
comments on the draft of Procedure for assessing the acceptability, in principle, of
vaccines for purchase by United Nations agencies (revision 2010): First draft -
Agence Française de Sécurité Sanitaire de Produits de Santé, France; BioManguinhos,
Oswaldo Cruz Foundation, Brazil; Center for Biologics Evaluation and Research, US
Food and Drug Administration, USA; Mr RD Morales, Centro Control Estatal de la
Calidad de los Medicamentos, Havana, Cuba; European Medicines Agency, London,
England; Dr M Eisenhawer, Swiss Agency for Therapeutic Products Inspectorates,
Bern, Switzerland; Dr I Feavers, National Institute for Biological Standards and
Control, Potters Bar, England; Dr M Ferguson, Independent, Norfolk, England; Dr J
Fournier-Caruana, World Health Organization, Geneva, Switzerland;
GlaxoSmithKline Biologicals, Belgium; International Federation of Pharmaceutical
Manufacturers and Associations, Switzerland; Dr S Lambert, World Health
Organization, Geneva, Switzerland; Dr V Maqueda, Independent, Buenos Aires,
Argentina; Dr J McEwen, Therapeutic Goods Administration, Woden ACT, Australia;
Dr J Milstien, University of Maryland, Maryland, USA; Agency of Food and Drug
Control, Indonesia; National Regulatory Authority, Iran; Dr C Nelson, Independent,
Pensylvania, USA; Panacea Biotec Limited, India; Serum Institute of India, India;
UNICEF Supply Division, Denmark. Second draft - Agence Française de Sécurité
Sanitaire de Produits de Santé, France; BioFarma, Indonesia; Biologicals E. Limited,
India; BioManguinhos, Oswaldo Cruz Foundation, Brazil; Crucell, Switzerland;
Federal State Unitary Enterprise of Chumakov Institute of Poliomyelitis and Viral
Encephalitides, Russian Federation; GAVI Alliance, Switzerland; GlaxoSmithKline
Biologicals, Belgium; GreenCross Corporation, Republic of Korea; Japan BCG
Laboratory, Japan; Dr H Langar, WHO Regional Office for the Eastern Mediterranean,
Cairo, Egypt; Novartis, Italy; Panacea Biotec Limited, India; Dr D Pfeifer, WHO
Regional Office for Europe, Copenhagen Denmark; Sanofi Pasteur, France; Serum
Institute of India, India; UNICEF Supply Division, Denmark.
43